Equillium (EQ) Competitors

$2.17 +0.11 (+5.44%)

As of 03:14 PM Eastern

EQ vs. VECT, ALLO, FDMT, PROK, and AVTX

Should you buy Equillium stock or one of its competitors? MarketBeat compares Equillium with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Equillium include VectivBio (VECT), Allogene Therapeutics (ALLO), 4D Molecular Therapeutics (FDMT), ProKidney (PROK), and Avalo Therapeutics (AVTX). These companies are all part of the "pharmaceutical products" industry.

How does Equillium compare to VectivBio?

VectivBio (NASDAQ:VECT) and Equillium (NASDAQ:EQ) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

In the previous week, Equillium had 2 more articles in the media than VectivBio. MarketBeat recorded 2 mentions for Equillium and 0 mentions for VectivBio. VectivBio's average media sentiment score of 0.00 equaled Equillium'saverage media sentiment score.

Company	Overall Sentiment
VectivBio	Neutral
Equillium	Neutral

VectivBio has higher earnings, but lower revenue than Equillium.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VectivBio	N/A	N/A	N/A	N/A	N/A
Equillium	$41.10M	3.32	-$22.40M	-$0.32	N/A

27.1% of Equillium shares are owned by institutional investors. 9.7% of VectivBio shares are owned by company insiders. Comparatively, 17.8% of Equillium shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

VectivBio's return on equity of 0.00% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VectivBio	N/A	N/A	N/A
Equillium	N/A	-61.43%	-53.72%

Equillium has a consensus price target of $7.67, indicating a potential upside of 254.94%. Given Equillium's stronger consensus rating and higher probable upside, analysts plainly believe Equillium is more favorable than VectivBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VectivBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Equillium	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Equillium beats VectivBio on 8 of the 10 factors compared between the two stocks.

How does Equillium compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Allogene Therapeutics' return on equity of -56.45% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Equillium	N/A	-61.43%	-53.72%

Allogene Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, Equillium has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market.

In the previous week, Equillium had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 2 mentions for Equillium and 1 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.21 beat Equillium's score of 0.00 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Equillium	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 27.1% of Equillium shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by company insiders. Comparatively, 17.8% of Equillium shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Equillium has higher revenue and earnings than Allogene Therapeutics. Equillium is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	23,808.75	-$190.89M	-$0.77	N/A
Equillium	$41.10M	3.32	-$22.40M	-$0.32	N/A

Allogene Therapeutics currently has a consensus price target of $8.52, suggesting a potential upside of 338.16%. Equillium has a consensus price target of $7.67, suggesting a potential upside of 254.94%. Given Allogene Therapeutics' higher possible upside, research analysts plainly believe Allogene Therapeutics is more favorable than Equillium.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Equillium	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Allogene Therapeutics beats Equillium on 8 of the 15 factors compared between the two stocks.

How does Equillium compare to 4D Molecular Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Equillium has lower revenue, but higher earnings than 4D Molecular Therapeutics. Equillium is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$88.24M	5.17	-$140.11M	-$2.57	N/A
Equillium	$41.10M	3.32	-$22.40M	-$0.32	N/A

In the previous week, 4D Molecular Therapeutics had 2 more articles in the media than Equillium. MarketBeat recorded 4 mentions for 4D Molecular Therapeutics and 2 mentions for Equillium. 4D Molecular Therapeutics' average media sentiment score of 0.25 beat Equillium's score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Equillium	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

4D Molecular Therapeutics currently has a consensus price target of $29.88, suggesting a potential upside of 242.21%. Equillium has a consensus price target of $7.67, suggesting a potential upside of 254.94%. Given Equillium's stronger consensus rating and higher probable upside, analysts clearly believe Equillium is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Equillium	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 27.1% of Equillium shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 17.8% of Equillium shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Equillium has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. 4D Molecular Therapeutics' return on equity of -36.83% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%
Equillium	N/A	-61.43%	-53.72%

4D Molecular Therapeutics has a beta of 2.77, meaning that its share price is 177% more volatile than the broader market. Comparatively, Equillium has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market.

Summary

4D Molecular Therapeutics beats Equillium on 10 of the 17 factors compared between the two stocks.

How does Equillium compare to ProKidney?

ProKidney (NASDAQ:PROK) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Equillium has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-8,131.50%	N/A	-21.39%
Equillium	N/A	-61.43%	-53.72%

ProKidney presently has a consensus price target of $7.40, suggesting a potential upside of 324.07%. Equillium has a consensus price target of $7.67, suggesting a potential upside of 254.94%. Given ProKidney's higher possible upside, analysts clearly believe ProKidney is more favorable than Equillium.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Equillium	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

51.6% of ProKidney shares are held by institutional investors. Comparatively, 27.1% of Equillium shares are held by institutional investors. 39.8% of ProKidney shares are held by company insiders. Comparatively, 17.8% of Equillium shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Equillium has higher revenue and earnings than ProKidney. Equillium is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	591.97	-$68.99M	-$0.53	N/A
Equillium	$41.10M	3.32	-$22.40M	-$0.32	N/A

In the previous week, ProKidney had 14 more articles in the media than Equillium. MarketBeat recorded 16 mentions for ProKidney and 2 mentions for Equillium. ProKidney's average media sentiment score of 0.03 beat Equillium's score of 0.00 indicating that ProKidney is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProKidney	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Equillium	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ProKidney has a beta of 1.7, indicating that its share price is 70% more volatile than the broader market. Comparatively, Equillium has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market.

Summary

ProKidney beats Equillium on 10 of the 16 factors compared between the two stocks.

How does Equillium compare to Avalo Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

Equillium has higher revenue and earnings than Avalo Therapeutics. Equillium is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	8,263.73	-$78.26M	-$5.46	N/A
Equillium	$41.10M	3.32	-$22.40M	-$0.32	N/A

In the previous week, Avalo Therapeutics had 15 more articles in the media than Equillium. MarketBeat recorded 17 mentions for Avalo Therapeutics and 2 mentions for Equillium. Avalo Therapeutics' average media sentiment score of 0.42 beat Equillium's score of 0.00 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Equillium	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Equillium's return on equity of -61.43% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-97.54%	-72.42%
Equillium	N/A	-61.43%	-53.72%

87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 27.1% of Equillium shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by company insiders. Comparatively, 17.8% of Equillium shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Avalo Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Equillium has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market.

Avalo Therapeutics presently has a consensus target price of $48.13, suggesting a potential upside of 184.68%. Equillium has a consensus target price of $7.67, suggesting a potential upside of 254.94%. Given Equillium's higher possible upside, analysts clearly believe Equillium is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
Equillium	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Equillium beats Avalo Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Equillium News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EQ vs. The Competition

Export

Metric	Equillium	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$136.32M	$3.35B	$6.33B	$12.27B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	-6.74	19.02	20.91	25.45
Price / Sales	3.32	278.31	520.52	73.05
Price / Cash	N/A	125.35	43.18	55.00
Price / Book	2.30	6.89	10.00	7.01
Net Income	-$22.40M	$24.23M	$3.54B	$335.03M
7 Day Performance	-16.14%	0.74%	0.38%	-0.43%
1 Month Performance	1.02%	-0.46%	-0.04%	0.99%
1 Year Performance	464.01%	63.21%	34.86%	34.43%

Equillium Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EQ Equillium	2.3118 of 5 stars	$2.16 +4.9%	$7.67 +254.9%	+434.6%	$136.32M	$41.10M	N/A	40
VECT VectivBio	N/A	$16.85 flat	N/A	N/A	$573.24M	$27.34M	N/A	30	High Trading Volume
ALLO Allogene Therapeutics	2.8846 of 5 stars	$2.30 +0.9%	$8.44 +266.9%	+63.8%	$563.09M	$20K	N/A	310
FDMT 4D Molecular Therapeutics	2.3909 of 5 stars	$10.34 -4.2%	$29.88 +188.9%	+120.0%	$540.52M	$88.24M	N/A	120	Gap Down
PROK ProKidney	1.7582 of 5 stars	$1.78 +0.6%	$7.40 +315.7%	+113.0%	$537.42M	$890K	N/A	3	Earnings Report Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EQ) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Equillium (EQ) Competitors

EQ vs. VECT, ALLO, FDMT, PROK, and AVTX

How does Equillium compare to VectivBio?

Summary

How does Equillium compare to Allogene Therapeutics?

Summary

How does Equillium compare to 4D Molecular Therapeutics?

Summary

How does Equillium compare to ProKidney?

Summary

How does Equillium compare to Avalo Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EQ vs. The Competition

Equillium Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Equillium (EQ) Competitors

EQ vs. VECT, ALLO, FDMT, PROK, and AVTX

How does Equillium compare to VectivBio?

Does the media refer more to VECT or EQ?

Which has stronger valuation & earnings, VECT or EQ?

Do institutionals & insiders believe in VECT or EQ?

Is VECT or EQ more profitable?

Do analysts rate VECT or EQ?

Summary

How does Equillium compare to Allogene Therapeutics?

Is ALLO or EQ more profitable?

Which has more volatility and risk, ALLO or EQ?

Does the media favor ALLO or EQ?

Do institutionals and insiders hold more shares of ALLO or EQ?

Which has stronger valuation and earnings, ALLO or EQ?

Do analysts recommend ALLO or EQ?

Summary

How does Equillium compare to 4D Molecular Therapeutics?

Which has better valuation and earnings, FDMT or EQ?

Does the media favor FDMT or EQ?

Do analysts rate FDMT or EQ?

Do insiders & institutionals hold more shares of FDMT or EQ?

Is FDMT or EQ more profitable?

Which has more volatility and risk, FDMT or EQ?

Summary

How does Equillium compare to ProKidney?

Is PROK or EQ more profitable?

Do analysts recommend PROK or EQ?

Do institutionals & insiders hold more shares of PROK or EQ?

Which has preferable valuation and earnings, PROK or EQ?

Does the media favor PROK or EQ?

Which has more risk & volatility, PROK or EQ?

Summary

How does Equillium compare to Avalo Therapeutics?

Which has better valuation & earnings, AVTX or EQ?

Does the media favor AVTX or EQ?

Is AVTX or EQ more profitable?

Do institutionals & insiders believe in AVTX or EQ?

Which has more volatility and risk, AVTX or EQ?

Do analysts rate AVTX or EQ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EQ vs. The Competition

Equillium Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools